J-CODES NOW AVAILABLE FOR ANTI-HER2 MBC THERAPIES

19 Dec 2013 2:38 PM | Lori Aubrey (Administrator)
The Centers for Medicare & Medicaid Services (CMS) have granted KADCYLA® (ado-trastuzumab emtansine) and PERJETA® (pertuzumab) permanent J-codes that go into effect January 1, 2014. The J-code for KADCYLA is J9354 (injection, ado-trastuzumab emtansine, 1 mg) and the J-code for PERJETA is J9306 (injection, pertuzumab, 1 mg). 

http://www.cgsmedicare.com/jc/pubs/news/2013/1213/cope24092.html

Please be sure to prepare your systems for the introduction of these 2 new codes.

For additional assistance, you can contact one of the dedicated Specialists at Genentech BioOncology™ Access Solutions at (888) 249‐4918, or visit Genentech‐Access.com/BioOncology for more information.

http://www.genentech-access.com/biooncology/hcp

Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software